• Contact
Augurex
  • Solutions
    • Solution Portfolio
    • Rheumatoid Arthritis
    • Axial Spondyloarthritis
    • Find a Test
  • Science
  • About
    • Company
    • Leadership
  • News
  • Careers
Select Page
Augurex has received $5M in funding from PacifiCan

Augurex has received $5M in funding from PacifiCan

by Simran Chahal | May 22, 2024 | Business, Health, News

Government of Canada invests almost $14 million to drive innovation and economic growth in Vancouver.Today, the Honourable Mary Ng, Minister of Export Promotion, International Trade and Economic Development on behalf of the Honourable Harjit S. Sajjan, Minister of...
Leading health publications are sharing the 14-3-3η blood test as part of the standard of care

Leading health publications are sharing the 14-3-3η blood test as part of the standard of care

by Simran Chahal | Oct 25, 2022 | Business, Health, News

Practical Pain Management highlights the 14-3-3η blood test The 14-3-3η blood test has been highlighted for earlier, more accurate diagnosis of rheumatoid arthritis by Practical Pain Management (PPM), a trusted publication providing evidence-based strategies for the...
14-3-3η: How Joint Involvement “Spreads”

14-3-3η: How Joint Involvement “Spreads”

by Simran Chahal | Mar 30, 2022 | Business, Health, News

14-3-3η: A Critical Mass of Data A recent systematic literature review describes a substantive body of evidence for 14-3-3η’s clinically important role along the whole continuum of rheumatoid arthritis and autoimmune patient care.Key Statements:14-3-3η helps to...
10 Years of Peer-Reviewed Studies Predicting and Informing the Prognosis Profile of Autoimmune Patients

10 Years of Peer-Reviewed Studies Predicting and Informing the Prognosis Profile of Autoimmune Patients

by Simran Chahal | Nov 11, 2021 | Business, Health, News

Recent journal publications are fortifying the clinically important role of the 14-3-3η blood test along the whole continuum of RA and autoimmune patient care. From RA meta-analysis data through to 14-3-3η expression in juvenile idiopathic arthritis and secondary...
Serum 14-3-3η A Predictor Of Secondary Sjögren’s Syndrome In SLE

Serum 14-3-3η A Predictor Of Secondary Sjögren’s Syndrome In SLE

by Simran Chahal | Jul 30, 2020 | Business, Health, News

Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)? With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist...
USPTO Awards Another Patent; New Data Demonstrating 14-3-3η as a Biomarker for Monitoring Therapy Response

USPTO Awards Another Patent; New Data Demonstrating 14-3-3η as a Biomarker for Monitoring Therapy Response

by Simran Chahal | Jan 1, 2019 | Business, Health, News

USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex’s Portfolio in the Diagnosis of Rheumatoid Arthritis (RA) On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From...
Page 9 of 11« First«…7891011»
©2024 Augurex Life Sciences. All Rights Reserved. Website by Vanooms Media Inc.